摘要
目的了解深圳市梅毒螺旋体(TP)抗体(抗-TP)阳性献血者中抗逆转录病毒治疗(ART)药物使用情况,评估人类免疫缺陷病毒(HIV)诊疗新趋势带来的血液安全风险。方法采用分层随机抽样方法选取2019年3月至2023年1月深圳地区血液筛查合格的重复献血者60例(阴性对照组),规律服用已知ART药物人群3例(阳性对照组),抗-TP阳性/抗-HIV阴性献血者353例(实验1组),抗-TP阳性/抗-HIV阳性献血者25例(实验2组),应用高效液相色谱-串联质谱(HPLC-MS/MS)方法检测各组血浆样本中8种ART药物浓度,分析ART药物使用情况。结果阳性对照组血浆采用1∶6稀释混样后ART药物仍可检出,实验1组和实验2组1∶6人份混合血浆阳性样本经拆分确证,实验2组检出1例ART药物阳性样本,该样本抗-HIV、蛋白免疫印迹、HIV RNA阳性,抗TP阳性献血者ART药物检出率为0.26%,实验1组ART药物检出率为0.00%,实验2组ART药物检出率为4.00%。结论深圳地区抗-TP阳性献血者中发现使用ART药物情况,合并HIV感染及高危性行为人群更可能使用ART药物。
Objective To find out the prevalence of antiretroviral therapy(ART)drugs among treponema pallidum(TP)antibody(anti-TP)positive blood donors in Shenzhen,and to assess the blood safety risks brought about by the new trends of human immunodeficiency virus(HIV)diagnosis and treatment.Methods A stratified random sampling method was used to select 60 repeat blood donors(negative control group)who passed blood screening in Shenzhen from March 2019 to January 2023,and 3 people who regularly took known ART drugs were named positive control group,358 anti-TP positive/anti-HIV negative blood donors were named experimental group 1,20 anti-TP positive/anti-HIV positive blood donors were named experimental group 2.The liquid chromatography-mass spectrometry(HPLC-MS/MS)was applied to detect the concentration of 8 ART drugs in plasma samples of each group,and the use of ART drugs was analyzed.Results After the positive control group′s plasma was diluted with a 1∶6 dilution mixture,the ART drugs could still be detected.The positive mixed plasma samples of 1∶6 people in Group 1 and Group 2 were split and validation,one ART drug positive sample was detected in Group 2,which was positive for anti-HIV,protein immunoblotting,and HIV RNA.The detection rate of ART drugs in anti-TP positive blood donors was 0.26%,0.00%in Group 1 and 4.00%in Group 2.Conclusion The use of ART drugs has been found among anti-TP positive blood donors in Shenzhen,and people with HIV infection and high-risk sexual behavior are more likely to use antiretroviral drugs.
作者
许晓绚
朱蕊
张爱佳
刘宜仲
戚陈英
李彤
陈婷婷
曾劲峰
王立林
XU Xiaoxuan;ZHU Rui;ZHANG Aijia;LIU Yizhong;QI Chenying;LI Tong;CHEN Tingting;ZENG Jinfeng;WANG Lilin(Shenzhen Blood Center,Shenzhen,Guangdong 518035,China;Shenzhen Baoan Central Blood Station,Shenzhen,Guangdong 518101,China)
出处
《国际检验医学杂志》
CAS
2024年第14期1692-1698,共7页
International Journal of Laboratory Medicine
基金
广东省医学基金项目(A2020259)
深圳市医学重点学科建设项目(SZXK070)
深圳市医疗卫生三名工程项目(SZSM202311032)
深圳市血液中心科研课题(SZBC202202,SZBC202303)。
